Form 4: BioXcel CEO Vimal Mehta Reports Stock Acquisitions
Insider Transaction Report
BioXcel Therapeutics CEO and President Vimal Mehta reported the acquisition of common stock through the exercise of Restricted Stock Units on September 14 and 15, 2025.
Summary
- Vimal Mehta, CEO and President of BioXcel Therapeutics, acquired shares of common stock through the exercise of Restricted Stock Units (RSUs).
- On September 14, 2025, 163 shares of common stock were acquired.
- On September 15, 2025, an additional 219 shares of common stock were acquired.
- Following these transactions, Mehta directly owns 20,493 shares of common stock.
- Mehta also indirectly owns 125 shares through a spouse and 480,343 shares through BioXcel LLC.
- The RSUs exercised on September 14, 2025, were part of a grant of 2,609 RSUs on March 14, 2022, vesting over time.
- The RSUs exercised on September 15, 2025, were part of a grant of 3,500 RSUs on March 15, 2023, also vesting over time.
Sentiment
Score: 6
Explanation: The filing reports routine insider transactions where the CEO acquired shares through RSU vesting, which is generally viewed as a neutral to slightly positive event indicating continued alignment with company performance.
Positives
- CEO Vimal Mehta increased direct beneficial ownership of BioXcel Therapeutics common stock through RSU exercises, aligning management interests with shareholders.
Industry Context
This report details routine insider equity transactions for BioXcel Therapeutics' CEO, which is a standard disclosure practice across all publicly traded companies and does not inherently reflect broader industry trends.
Related Party Transactions
- Vimal Mehta, as an executive officer and sole board member of BioXcel Holdings, Inc. (parent company), and an executive officer and manager of BioXcel LLC (subsidiary), is deemed to have indirect beneficial ownership of 480,343 shares held by BioXcel LLC. Mehta disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Stakeholder Impact
- Shareholders: Provides transparency regarding insider holdings and management's vested interest in the company's stock performance.
- Management: Vimal Mehta's compensation structure includes equity awards (RSUs) that convert to common stock, aligning his incentives with long-term company value.
Key Dates
| Date | Description |
|---|---|
| 03/14/2022 | Grant date for 2,609 Restricted Stock Units (RSUs) to Vimal Mehta. |
| 03/15/2023 | Grant date for 3,500 Restricted Stock Units (RSUs) to Vimal Mehta. |
| 09/14/2025 | Transaction date for the acquisition of 163 shares of common stock by Vimal Mehta through RSU exercise. |
| 09/15/2025 | Transaction date for the acquisition of 219 shares of common stock by Vimal Mehta through RSU exercise. |
| 09/16/2025 | Signature date of the Form 4 filing by Attorney-in-Fact for Vimal Mehta. |
Keywords
BioXcel Therapeutics, BTAI, Vimal Mehta, Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, RSU, CEO, President, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.